Robotic-Assisted Percutaneous Coronary Intervention

Overview

Percutaneous coronary intervention is a safe procedure. However, its execution is manual, fully operator-dependent. The procedure is also associated with radiation exposure to patients and physicians. This study will evaluate the robotic assisted percutaneous coronary intervention as an alternative to manual operation.

Full Title of Study: “Robotic-Assisted Percutaneous Coronary Intervention – A Safety and Effectiveness Study Applied to the Brazilian Public Health System”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: February 10, 2020

Interventions

  • Procedure: Robotic Assisted Percutaneous Coronary Intervention
    • Robotic Assisted Percutaneous Coronary Intervention

Arms, Groups and Cohorts

  • Experimental: Robotic Assisted Percutaneous Coronary Intervention

Clinical Trial Outcome Measures

Primary Measures

  • Procedure Complications
    • Time Frame: 1 day
    • Death or non-fatal major acute complications on the target vessel (thrombosis, myocardial infarction, perforation or non-planned invasive treatment).
  • Procedure Success
    • Time Frame: 1 day
    • Robotic Assisted Procedure Success

Secondary Measures

  • Occurence of Major Events
    • Time Frame: 1 month
    • Death, stent thrombosis, Myocardial Infarction, Stroke

Participating in This Clinical Trial

Inclusion Criteria

1. Age> = 18 years; 2. Symptomatic ischemic heart disease and / or objective evidence of myocardial ischemia with one or more target lesions; 3. Elective for percutaneous procedure (i.e. performed in a non-urgent context) 4. The target lesion (s) must be obstructive, with stenosis diameter > 50% (visual analysis); 5. The interventional planning of all target lesions should include robotic manipulation in at least one treatment, as judged by the operator; 6. Acceptable candidate for myocardial revascularization surgery. Exclusion Criteria:

1. ST-segment elevation myocardial infarction in the last 48 hours before the index procedure; 2. Ejection fraction <30%; 3. Impaired renal function (creatinine> 2.0 mg / dL) or calculated creatinine clearance <30 ml / min; 4. Platelet count <100,000 cells / mm 3 or> 700,000 cells / mm 3; 5. Total Leucocytes count <3,000 cells / mm 3; 6. Suspected or documented active liver disease (including laboratory evidence of hepatitis); 7. Heart transplant recipient; 8. Allergies known to aspirin, clopidogrel, ticlopidine, ticagrelor, prasugrel, heparin, antiproliferative agents of the limus family, or stainless steel; 9. Patient with a life expectancy of less than 1 month; 10. Any significant medical condition that in the opinion of the investigator may interfere with the patient's ideal participation in this study; 11. Participation in other research in the last 12 months, unless there may be direct benefit to the research subject; 12. Any invasive cardiac or non-cardiac treatment scheduled within the first month after the index procedure. Angiographic exclusion criteria 1. Need for non-robotic (i.e. manual) treatment of another injury in the index procedure or in the first month; 2. Target lesion not accessible by robotic treatment, according to the judgment of the operator; 3. Unprotected coronary artery trunk lesion (stenosis> 50%); 4. Angiographic thrombus; 5. Target lesion in surgical graft; 6. Total occlusion (TIMI 0 or 1 anterograde flow)

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Hospital Israelita Albert Einstein
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Pedro Lemos, PhD, +55 (11) 2151-4306, pedro.lemos@einstein.br

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.